I Peace, Inc., a GMP cell and gene therapy CDMO has announced the launch of its latest GMP-grade induced pluripotent stem cell (iPSC) line, which is homozygous for key HLA types. Developed from a healthy 26-year-old donor, the line provides
PharmaLogic Holdings Corp. , a contract development and manufacturing organisation (CDMO) specialising in radiopharmaceutical solutions, has officially opened its Los Angeles facility following extensive renovations. Acquired in 2022, this state-of-the-art centre is equipped with advanced technology to support the production and
Naobios has reached a critical milestone in the production of an HIV-1 vaccine candidate for Korean-Canadian biotechnology firm Sumagen Canada Inc. The achievement marks the completion of bench-scale production of Sumagen’s SAV001 vaccine, a genetically modified, whole-killed HIV vaccine designed
Experic, a US-based contract development and manufacturing organisation (CDMO), has received a substantial investment led by Philadelphia-based healthcare equity firm 1315 Capital. Existing investors, including East Seattle Partners, Harro Höfliger Packaging Systems, and Kineticos Ventures, also participated in this financing
Ardena, a pharmaceutical contract development and manufacturing organisation (CDMO), has announced an expansion of its bioanalytical services in the Netherlands. The investment includes a 3,000-square-foot lab at Pivot Park in Oss, expected to be operational by Q1 2025, alongside upgrades
Merck, the science and technology company, has announced a €70 million investment to expand its Bioconjugation Center of Excellence in St. Louis, Missouri, USA. This development will triple the site’s capacity, supporting bioconjugate drug production for clients worldwide. The company’s
Phosphorex, a contract development and manufacturing organization (CDMO) focused on drug delivery, has announced the opening of its Lipid Nanoparticle Innovation & Training Center in Hopkinton, Massachusetts. The centre aims to accelerate the success of clients’ drug development projects by
WuXi Biologics (“WuXi Bio”) has announced the launch of its WuXia RidGS platform, aimed at improving the development of therapeutic proteins, particularly monoclonal antibodies (mAbs). This innovative platform employs a glutamine synthetase (GS)-knockout CHO expression system, which leverages zinc finger
Sai Life Sciences, an Indian Contract Research, Development and Manufacturing Organization (CRDMO), announced the receipt of Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA). The reports pertain to its R&D facility (Unit II) in Hyderabad and
Medicines for Malaria Venture (MMV), in partnership with Quotient Sciences, has launched a Phase 1 clinical trial for MMV371, a new long-acting injectable designed to prevent malaria. The trial, currently underway with healthy volunteers in Nottingham, UK, will evaluate the
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
